Protective effect of pioglitazone, a PPARγ ligand, in a 3 nitropropionic acid model of Huntington's disease

Brain Research Bulletin

Volumn 85, Issue 3-4, 2011, Pages 231-237

  Napolitano, Maddalena ^a,b   Costa, Loredana ^a   Palermo, Rocco ^a   Giovenco, Alessandro ^a   Vacca, Alessandra ^c   Gulino, Alberto ^a,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d IRCCS NEUROMED   (Italy)

Author keywords

Acetylation; Huntington's disease; NF B; NOS; Pioglitazone; PPAR

Indexed keywords

3 NITROPROPIONIC ACID; GLUTAMINE; HISTONE DEACETYLASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PENICILLIN G; PIOGLITAZONE; STREPTOMYCIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; GENE TRANSLOCATION; HISTONE MODIFICATION; HUNTINGTON CHOREA; MITOCHONDRION; NERVE CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; CORPUS STRIATUM; GENE EXPRESSION REGULATION; HISTONE DEACETYLASES; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEURONS; NEUROPROTECTIVE AGENTS; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE II; NITRO COMPOUNDS; PROPIONIC ACIDS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, WISTAR; RNA, MESSENGER; THIAZOLIDINEDIONES;

EID: 79957858160     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2011.03.011     Document Type: Article

References (39)

1. Ashburner B., Westerheide S.D., Baldwin A.S. The p65 (RelA) subunit of NF-kappa B interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 2001, 21:7065-7077.
2. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 1993, 13:4181-4192.
3. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
4. Berger J., Moller D.E. The mechanisms of action of PPARs. Annu. Rev. Med. 2002, 53:409-435.
5. Calao M., Burny A., Quivy V., Dekoninck A., Van Lint C. A pervasive role of histone acetyltransferases and deacetylases in an NF-κB-signaling code. Trends Biochem. Sci. 2008, 33:339-349.
6. Chen L., Fischle W., Verdin E., Greene W.C. Duration of nuclear NF-kB action regulated by reversible acetylation. Science 2001, 1653-1657.
7. Dehmer T., Heneka M.T., Sastre M., Dichgans J., Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IkappaBalpha induction and block of NFkappaB and iNOS activation. J. Neurochem. 2004, 88:494-501.
8. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., Smith K., Kowall N.W., Ratan R.R., Carter R.L., Hersch S.M. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 2003, 23:9418-9427.
9. Fridmacher V., Kaltschmidt B., Goudeau B., Ndiaye D., Rossi F.M., Pfeiffer J., Kaltschmidt C., Israel A., Memet S. Forebrain-specific neuronal inhibition of nuclear factor-kB activity leads to loss of neuroprotection. J. Neurosci. 2003, 23:9403-9408.
10. Fuenzalida K., Quintanilla R., Ramos P., Piderit D., Fuentealba R.A., Martinez G., Inestrosa N.C., Bronfman M. Peroxisome proliferator-activated receptor γ up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J. Biol. Chem. 2007, 282:37006-37015.
11. Gao Z., Chiao P., Zhang X., Zhang X., Lazar M.A., Seto E., Young H.A., Ye J. Coactivators and corepressors of NF-κB in IκBα gene promoter. J. Biol. Chem. 2005, 280:21091-21098.
12. Gil J.M., Rego A.C. Mechanisms of neurodegeneration in Huntington's disease. Eur. J. Neurosci. 2008, 27:2803-2820.
13. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
14. Jin Y.N., Johnson G.V.W. The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. J. Bioenerg. Biomembr. 2010, 42:199-205.
15. Kaltschmidt B., Uherek M., Wellmann H., Volk B., Kaltschmidt C. Inhibition of NF-kB potentiates amyloid-mediated neuronal apoptosis. PNAS 1999, 96:9409-9414.
16. Kazantsev A.G., Thompson L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 2008, 7:854-868.
17. Kersten S., Desvergne B., Wahli W. Roles of PPARs in health and disease. Nature 2000, 405:421-424.
18. Kiaei M. Peroxisome proliferator-activated receptor-γ in amyotrophic lateral sclerosis and Huntington's disease. PPAR Res. 2008, 8 pp.
19. Kiernan R., Brès V., Ng R.W.M., Coudart M.P., El Messaoudi S., Sardet C., Jin D.Y., Emiliani S., Benkirane M. Post-activation turn-off of NF-κB-dependent transcription is regulated by acetylation of p65. J. Biol. Chem. 2003, 278:2758-2766.
20. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
21. Mattson M.P., Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. J. Clin. Invest. 2001, 107:247-254.
22. Mattson M.P., Meffert M.K. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ. 2006, 13:852-860.
23. Meffert M.K, Chang J.M., Wiltgen B.J., Fanselow M.S., Baltimore D. NF-kappa B functions in synaptic signaling and behavior. Nat. Neurosci. 2003, 61:1072-1078.
24. Meffert M.K., Baltimore D. Physiological functions for brain NF-KB. Trends Neurosci. 2005, 28:37-43.
25. Napolitano M., Zei D., Centonze D., Palermo R., Bernardi G., Vacca A., Calabresi P., Gulino A. NFkB/NOS cross-talk induced by mitochondrial complex II inhibition: Implications for Huntington's disease. Neurosci. Lett. 2008, 241-246.
26. Oliveira J.M.A. Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum. J. Neurochem. 2010, 114:1-12.
27. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-bold gamma. Nature 2005, 437:759-763.
28. Park G.Y., Wang X., Hu N., Pedchenko T.V., Blackwell T.S., Christman J.W. NIK is involved in nucleosomal regulation by enhancing histone H3 phosphorylation, by IKKα. J. Biol. Chem. 2006, 281:18684-18690.
29. Quinn L.P., Crook B., Hows M.E., Vidgeon-Hart M., Chapman H., Upton N., Medhurst A.D., Virley D.J. The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br. J. Pharmacol. 2008, 154:226-233.
30. Quintanilla R.A., Jin Y.N., Fuenzalida K., Bronfman M., Johnson G.V.W. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-γ (PPARγ) in the pathogenesis of Huntington's disease. J. Biol. Chem. 2008, 283:25628-25637.
31. Quivy V., Van Lint C. Regulation at multiple levels of NF-κB-mediated transactivation by protein acetylation. Biochem. Pharmacol. 2004, 68:1221-1229.
32. Rizzo G., Fiorucci S. PPARs and other nuclear receptors in inflammation. Curr. Opin. Pharmacol. 2006, 6:421-427.
33. Sadri-Vakili G., Cha J.H.J. Mechanisms of disease: histone modifications in Huntington's disease. Nat. Clin. Pract. Neurol. 2006, 2:330-338.
34. Saha R.N., Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ. 2006, 13:539-550.
35. Trushina E., McMurray C.T. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 2007, 145:1233-1248.
36. Viatour P., Legrand-Poels S., van Lint C., Warnier M., Merville M.P., Gielen J., Piette J., Bours V., Chariot A. Cytoplasmic IκBα increases NF-κB-independent transcription through binding to histone deacetylase (HDAC) 1 and HDAC3. J. Biol. Chem. 2003, 278:46541-46548.
37. Willson T.M., Lambert M.H., Kliewer S.A. Peroxisome proliferator-activated receptor-γ and metabolic disease. Annu. Rev. Biochem. 2001, 70:341-367.
38. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9:47-59.
39. Yu Z., Zhou D., Bruce-Keller A.J., Kindy M.S., Mattson M.P. Lack of the p50 subunit of nuclear factor-kappaB increases the vulnerability of hippocampal neurons to excitotoxic injury. J. Neurosci. 1999, 19:8856-8865.